Valerio Therapeutics SA
PAR:ALVIO

Watchlist Manager
Valerio Therapeutics SA Logo
Valerio Therapeutics SA
PAR:ALVIO
Watchlist
Price: 0.155 EUR -6.91%
Market Cap: 75.8m EUR
No Transactions Found

We don't have any information about ALVIO's insider trading.

Global
Insiders Monitor

Valerio Therapeutics SA
Glance View

Market Cap
75.8m EUR
Industry
Biotechnology

Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of drugs for the treatment of orphan diseases. The company is headquartered in Paris, Ile-De-France and currently employs 25 full-time employees. The company went IPO on 2005-07-12. The firm targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). The company aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.

ALVIO Intrinsic Value
0.065 EUR
Overvaluation 58%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top